Krzysztof Leśniewski-Kmak

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

Martin Reck, Michael Schenker, Ki Hyeong Lee et al. · European Journal of Cancer · 2019 · 212 citations · Full text

MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study

Tamas Hickish, Thierry André, Lucjan Wyrwicz et al. · The Lancet Oncology · 2017 · 153 citations

Novel Antibody Treatment, Medicine, Immunology +7

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial

J Cassidy, J.-Y. Douillard, C.J. Twelves et al. · British Journal of Cancer · 2006 · 124 citations · Full text

Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention--review of the literature.

J Wojtacki, Ewa Lewicka, Krzysztof Leśniewski-Kmak · PubMed · 2001 · 110 citations

Clinical Course, Cardiomyopathy, Heart Failure +15